Trial Profile
Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms RC14/055
- 09 Dec 2016 New trial record